ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
Author(s): FORD D, EASTON DF, BISHOP DT, NAROD SA, GOLDGAR DE, HAITES N, MILNER B, ALLAN L, PONDER BAJ, PETO J, SMITH S, STRATTON M, LENOIR GM, FEUNTEUN J, LYNCH H, ARASON A, BARKARDOTTIR R, EGILSSON V, BLACK DM, KELSELL D, SPURR N, DEVILEE P, CORNELISSE CJ, VARSEN H, BIRCH JM, SKOLNICK M, SANTIBANEZKOREF MS, TEARE D, STEEL M, PORTER D, COHEN BB, CAROTHERS A, SMYTH E, WEBER B, NEWBOLD B, BOEHNKE M, COLLINS FS, CANNONALBRIGHT LA, GOLDGAR D
Source: LANCET    Volume: 343    Issue: 8899    Pages: 692-695    Published: MAR 19 1994  
Times Cited: 994     References: 12     
Abstract: Germline mutations in a gene on chromosome 17q known as BRCA1 are responsible for a large proportion of inherited predispositions to breast and ovarian cancer.

In 33 families with evidence of linkage to BRCA1, we estimated the risks of breast and ovarian cancer from the occurrence of second cancers in individuals with breast cancer, and examined the risks of other cancers in BRCA1 carriers. 26 contralateral primary breast cancers occurring more than 3 years after a first breast cancer were observed before age 70, giving an estimated cumulative risk of breast cancer in gene carriers of 87% by age 70. 23 primary ovarian cancers occurred in women with a previous breast cancer, resulting in an estimated cumulative risk of ovarian cancer of 44% by age 70. 87 cancers other than breast or ovarian cancer were observed in individuals with breast or ovarian cancer and their first-degree relatives compared with 69.3 expected, based on national incidence rates. Significant excesses were observed for colon cancer (estimated relative risk [RR] to gene carriers 4.11 [95% Cl 2.36-7.15]) and prostate cancer(3.33 [1.78-6.20]). No significant excesses (or deficits) were noted for cancers of other sites.

Our study provides estimates of breast and ovarian cancer risks which are useful for counselling BRCA1-mutation carriers. It also shows that carriers are at increased risk of colon and prostate cancer, which may be of clinical significance in certain families if the risks are associated with specific mutations.

Document Type: Article
Language: English
Reprint Address: FORD, D (reprint author), INST CANC RES, EPIDEMIOL SECT, BLOCK D, BELMONT SM2 5NG, SURREY ENGLAND
Addresses:
1. ST JAMES HOSP, ICRF, GENET EPIDEMIOL UNIT, LEEDS, ENGLAND
2. MONTREAL GEN HOSP, MONTREAL, PQ CANADA
3. UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA
4. UNIV ABERDEEN, ABERDEEN, SCOTLAND
5. CANC RES CAMPAIGN, LONDON, ENGLAND
6. INST CANC RES, LONDON, ENGLAND
7. INT AGCY RES CANC, LYON, FRANCE
8. UNIV ICELAND, REYKJAVIK, ICELAND
9. IMPERIAL CANC RES FUND, LEEDS, W YORKSHIRE ENGLAND
10. LEIDEN UNIV, LEIDEN, NETHERLANDS
11. FDN DETECT HEREDITARY TUMOURS, LEIDEN, NETHERLANDS
12. CHRISTIE HOSP & HOLT RADIUM INST, MANCHESTER M20 9BX, LANCS ENGLAND
13. IMPERIAL CANC RES FUND, LONDON, ENGLAND
14. MRC, HUMAN GENET UNIT, EDINBURGH, MIDLOTHIAN SCOTLAND
15. UNIV MICHIGAN, ANN ARBOR, MI 48109 USA
16. INST CANC RES, CAMBRIDGE, CAMBS ENGLAND
Publisher: LANCET LTD, 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
Subject Category: Medicine, General & Internal
IDS Number: NB809
ISSN: 0140-6736
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo